Asgard Therapeutics today announces the appointments of Dr Cristina Csimma as an independent member of its Board of Directors, and Prof Ignacio Melero and Prof Brian Brown to its Clinical and Scientific Advisory Board.
Read moreAsgard Therapeutics today announces the appointment of experienced immunology drug development specialist Shane Olwill as Chief Development Officer.
Read moreAsgard Therapeutics, Lund University and Herlev Hospital secure €2.5m in EIC funding to advance TIL-based immunotherapy.
Read moreAsgard Therapeutics today announces the publication of key proof-of-concept data supporting its lead program, AT-108, in the high-impact, peer-reviewed journal, Science.
Read moreAsgard Therapeutics today announced it selected Exothera S.A. (“Exothera”), a leading provider of nucleic acids and viral vector development and manufacturing services, for process development up to clinical Phases I/II manufacturing of its candidate AT-108.
Read moreAsgard Therapeutics today announce a €30 million Series A financing. The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
Read moreAsgard Therapeutics announces today the presentation of a poster showcasing positive in vivo data. These data will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will take place in San Diego, California November 1-5, 2023.
Read moreAsgard Therapeutics proudly announces the addition of Dr. Ulrich Lauer, MD, and Dr. Aurélien Marabelle, MD PhD to its Scientific Advisory Board (SAB) during its second SAB annual meeting. The addition of these two leading experts in clinical immuno-oncology is a timely complement to Asgard's SAB, given the recent milestone of achieving preclinical proof-of-concept to AT-108 lead program.
Read more